Clinical Trial Update: A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

View source ↗

Summary

Post-marketing study evaluating eslicarbazepine acetate as an adjunctive treatment for partial-onset seizures; the EPOS trial (E2093-E044-404) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial-onset Seizures

Drugs mentioned

• APTIOM (Eslicarbazepine acetate)

Snippet

Sponsor: Eisai Inc. | Conditions: Partial Onset Seizures | Status: COMPLETED